NASDAQ:ZEAL

Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$17.59
$17.59
50-Day Range
$16.54
$19.20
52-Week Range
$9.93
$32.94
Volume
N/A
Average Volume
4,965 shs
Market Capitalization
$818.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ZEAL stock logo

About Zealand Pharma A/S Stock (NASDAQ:ZEAL)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

ZEAL Stock News Headlines

Correction to Company announcement – No. 23 / 2024
What is Medicare Supplement Insurance?
Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you.
Pharmac's perpetually stretched budget
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Zealand Pharma's Annual General Meeting 2024
See More Headlines
Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZEAL
Employees
355
Year Founded
N/A

Profitability

Net Income
$-161,990,000.00
Net Margins
-565.44%
Pretax Margin
-364.34%

Debt

Sales & Book Value

Annual Sales
$46.54 million
Book Value
$3.38 per share

Miscellaneous

Free Float
45,514,000
Market Cap
$818.60 million
Optionable
Not Optionable
Beta
1.45
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Adam Sinding Steensberg M.D. (Age 48)
    Pres & CEO
    Comp: $680.16k
  • Mr. Ivan Mourits Moller (Age 50)
    Chief Operating Officer
  • Lani Pollworth Morvan
    Investor Relations & Communications Officer
  • Mr. Mads Kronborg
    Head of Investor Relations & Communication
  • Mr. Ravinder Chahil
    Sr. VP & Gen. Counsel
  • Ms. Christina Sonnenborg Bredal (Age 37)
    Sr. VP and Global Head of People & Organization
  • Ms. Hanne Heidenheim Bak (Age 69)
    Sr. Project Director, R&D Operations Mang. and Employee Representative Director
  • Dr. Jens Damsgaard Mikkelsen M.D.
    Head of Molecular Pharmacology
  • Dr. Danilo Verge
    Head of Global Medical Affairs
  • Dr. David M. Kendall M.D. (Age 60)
    Chief Medical Officer

ZEAL Stock Analysis - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZEAL shares.
View ZEAL analyst ratings
or view top-rated stocks.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($4.61) EPS for the quarter, beating analysts' consensus estimates of ($6.31) by $1.70. The company had revenue of $16.87 million for the quarter, compared to analysts' expectations of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 111.04% and a negative net margin of 565.44%. During the same quarter last year, the business earned ($0.90) earnings per share.

What other stocks do shareholders of Zealand Pharma A/S own?
When did Zealand Pharma A/S IPO?

Zealand Pharma A/S (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

This page (NASDAQ:ZEAL) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners